| 33 |
Oral Abstracts (Session 2 of 5)
|
Moderator: John M. MacDonald, MD, FACS (Presentation 33.5) PVP-iodine liposome hydrogel—a novel concept in wound therapy enhances epithelialization and reduces loss of mesh grafts PM Vogt, MD, PhD, Plastische, Hand-und Wiederherstellungschirurgie, Medizinische Hochschule Hannover, Germany; Karen Reimer, MD, PhD, Mundipharma Research GmbH, Limburg, Germany; Oliver Rossbach, MD, Joerg Hauser, MD, Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte, BG-Kliniken, Ruhr-Universität, Germany; B Bosse, Msc; W Fleischer, MD, Mundipharma Research GmbH, Limburg, Germany, Bochum Introduction: A novel concept in wound healing, combining a moist wound environment and antisepsis, was assessed in a clinical monocentric, randomized, observer blind, phase 3 study. Methods: Polyvinyl-pyrrolidone (PVP)-iodine liposomal hydrogel (PLH)*, a new wound healing product, was investigated in patients receiving meshed skin grafts after burns or reconstructive procedures. Graft sites of 167 patients were dressed either with PLH (n=83) covered with gauze (Jellonet®) or gauze only (n=84). Starting on Day 3, the wounds were assessed clinically by photoplanimetry (epithelialization), measurement of impedance (surface moisture), pain, and discomfort. Also, thyroid hormones (T3, T4, TSH) were measured. Results: Neoepithelialization was significantly increased with PLH compared to gauze (91.2+22.8% vs. 82.3%+28.6, p< 0.0001), while graft loss was significantly reduced under PLH application (p=0.0087) without relevant adverse events or clinically relevant changes of thyroid hormones. Discussion: The rationale of this new PVP-iodine liposomal hydrosomal formulation, PLH, is based on the properties of liposomes to provide higher moisture and release phospholipids into the wound, release PVP-iodine at a lower rate, and target the substance more exactly by interaction with the microorganisms’ surface. This novel concept in wound therapy significantly enhances epithelialization and reduces loss of mesh grafts. * Repithel® Mundipharma, GmbH, Limburg, Germany |
|